ClinicalTrials.gg
RecruitingNCT05792527Updated Mar 31, 2023

L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis

A Phase 3 interventional study of L-carnitine in Rheumatoid Arthritis, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-31.

Sponsored by Tanta University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Arthritis, Rheumatoid by Tanta University — 11 open to participants now, 11 under way, 3 of them phase 3. Arthritis, Rheumatoid · Tanta University.

Planned enrollment
10th of 14
46 · median 63
Started
2023
with 1 other
Phase 3
4 of 15
3 open now
Primary completion
2025-03
later than 2 of 10 live
Registered
5th of 15
by date

Among the 15 studies in Arthritis, Rheumatoid by Tanta University, this one is the 10th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 in phase 3, reaches primary completion later than 2 of the 10 other live ones, and was the 5th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

11 of the 15 studies in Arthritis, Rheumatoid by Tanta University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Arthritis, Rheumatoid by Tanta University, or all of them as a file.
02

Study summary

This study aims at evaluating the possible efficacy and safety of L-carnitine in rheumatoid arthritis via targeting Jak/STAT pathway and TGF-β1

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria (9) i.e., 28 joints disease activity score (DAS-28) >2.6.
  • Patients receive the conventional DMARDs
  • Both sexes.
  • Age range between 18 and 70 years old.

Exclusion criteria

Exclusion Criteria:

  • Patients with heart disease (congestive heart failure, arrhythmia, hypertension, ischemic heart diseases), diabetes, active infection, other illness except rheumatoid arthritis.
  • Patients with renal and hepatic dysfunction.
  • Patients receiving biological DMARDs.
  • Patients receiving oral prednisolone greater than 15 mg/day.
  • Patients with to study medications.
  • Patients using antioxidants.
  • Pregnant and lactating females.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • No intervention
    control group

    this group will include 23 patients which will receive the traditional therapy of RA for 3 months.

  • Active comparator
    L-carnitine group

    this group will include 23 patients which will receive 500mg L-carnitine two times daily after meal plus the traditional therapy of RA for 3 months.

    Drug: L-carnitine

Interventions

06

What researchers measure

Primary outcomes

  1. The change in DAS-28-CRP score

    Patients will undergo clinical assessment according to DAS-28-CRP score

    Time frame: 3 months

  2. The change in Multidimensional Health Assessment Questionnaire (MDHAQ) score

    Time frame: 3 months

Secondary outcomes

  1. The change in serum level of C-reactive protein (CRP)

    Blood samples will be collected at base line and after 3 months

    Time frame: 3 months

  2. The change in serum level of Signal transducer and activator of transcription 3(STAT 3).

    Blood samples will be collected at base line and after 3 months

    Time frame: 3 months

  3. The change in serum level of Transforming growth factor β1(TGF-β1).

    Blood samples will be collected at base line and after 3 months

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2025, 24 months after the start.

Of 148 phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 40. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2023
First posted
Mar 31, 2023
StartActual
Mar 5, 2023
Primary completionEst.
Mar 5, 2025
CompletionEst.
Mar 5, 2026
Last update
Mar 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05792527
Lead sponsor
Tanta University
Responsible party
Abdallah Abo-Elazm Shebl Eldisouky (principal investigator, Tanta University) — Principal investigator
First posted
Mar 31, 2023
Start date
Mar 5, 2023
Primary completion
Mar 5, 2025 (estimated)
Completion
Mar 5, 2026 (estimated)
Last update
Mar 31, 2023

Study contacts

Abdallah A Eldisouky
Contact
PG_165476@pharm.tanta.edu.eg
201279142631

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carnitine

Start the discussion